Current drug safety最新文献_第7页

Erythema Multiforme Reactions Following Pfizer/BioNTech (Tozinameran) Vaccination: Two Case-Reports with Positive Rechallenge and Review of the Literature. 辉瑞/BioNTech（Tozinameran）疫苗接种后的多形性红斑反应：两例复查阳性病例报告及文献综述。

IF 1.1

Current drug safety Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230725101846

Ons Charfi, Ghozlane Lakhoua, Khouloud Berrim, Sarrah Kastalli, Talel Badri, Imen Aouinti, Riadh Daghfous, Ahmed Zaiem, Sihem El Aidli

{"title":"Erythema Multiforme Reactions Following Pfizer/BioNTech (Tozinameran) Vaccination: Two Case-Reports with Positive Rechallenge and Review of the Literature.","authors":"Ons Charfi, Ghozlane Lakhoua, Khouloud Berrim, Sarrah Kastalli, Talel Badri, Imen Aouinti, Riadh Daghfous, Ahmed Zaiem, Sihem El Aidli","doi":"10.2174/1574886318666230725101846","DOIUrl":"10.2174/1574886318666230725101846","url":null,"abstract":"Aim: Pfizer/BioNTech (BNT162b2) is a COVID-19 vaccine with a reassuring safety profile. The main adverse reactions are mild local reactions. Cutaneous reactions are generally minor. The most common cutaneous reaction reported was a local injection-site reaction.Case study: Here we present 2 cases of erythema multiform (EM) following BNT162b2 vaccination with positive rechallenge. The 1st case was about a 51-year-old woman who developed 5 days after the 1st dose of the mRNA Pfizer/BioNTech (BNT162b2) a macular, erythematous, roundshaped lesions on the hands, knees and soles. She experienced a positive rechallenge one month later. In the 2nd case, a 55-year-old man presented 6 days following the 2nd shot of the mRNA Pfizer/ BioNTech (BNT162b2), targetoid eruption on the upper and lower members. The patient reported that he had the same skin lesions in ankles and soles few days following the 1st shot of the same vaccine.Conclusion: Few cases of EM following COVID-19 vaccination were reported in the literature and positive rechallenge in only one case. Rechallenge was not performed in most cases. Our two cases are particular because of the positive rechallenge in both patients. This is the gold standard to confirm that the vaccine was the culprit agent in inducing EM.","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9866240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of Dermatomyositis after Pfizer BioNTeh COVID-19 Vaccine: A Case Report. 辉瑞 BioNTeh COVID-19 疫苗引发皮肌炎：病例报告。

IF 1.5

Current drug safety Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230614164607

Imen Aouintia, Wiem Daly, Ghozlane Lakhoua, Widd Kaabi, Ons Charfi, Sana Debbeche, Sarrah Kastalli, Ahmed Zaiem, Sihem El Aidli

{"title":"Development of Dermatomyositis after Pfizer BioNTeh COVID-19 Vaccine: A Case Report.","authors":"Imen Aouintia, Wiem Daly, Ghozlane Lakhoua, Widd Kaabi, Ons Charfi, Sana Debbeche, Sarrah Kastalli, Ahmed Zaiem, Sihem El Aidli","doi":"10.2174/1574886318666230614164607","DOIUrl":"10.2174/1574886318666230614164607","url":null,"abstract":"Introduction: The Coronavirus Disease 2019 (COVID-19) pandemic led to the fast development of vaccines, which is considered a medical advance in healthcare. With the extensive vaccination campaign performed worldwide, many adverse events following immunization (AEFI) were reported. Most of them were flu-like symptoms, mild and self-limiting. However, serious adverse events, such as dermatomyositis (DM), an idiopathic autoimmune connective tissue disease, have also been reported.Case presentation: In this report, we describe a case of skin erythema, edema, and diffuse myalgia attributed at first to Pfizer BioNTeh, COVID-19 vaccination, given the temporal relationship and the absence of significant medical history. The causality assessment score was I1B2. However, after completing the etiological assessment, an invasive breast carcinoma was identified, and we retained the diagnosis of paraneoplastic DM.Conclusion: This study underlines the importance of completing the etiological assessment before attributing any adverse reaction to vaccination to maintain optimal patient care.","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9633642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Remimazolam and Remifentanil Use Induced Severe Respiratory Depression and Laryngeal Spasm During Intravenous Sedation and Analgesia: A Case Report. 静脉镇静镇痛时使用雷马唑仑和瑞芬太尼引起严重呼吸抑制和喉痉挛1例。

IF 1.5

Current drug safety Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230517101142

Zhijun Xin, Ning Wang, Huaizhou Wang

引用次数: 1

The Gambia Death Story: 66 Children Died! 冈比亚的死亡故事：66 名儿童死亡！

IF 1.5

Current drug safety Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230726161911

Sumel Ashique

引用次数: 0

Treatment Modalities for Trigeminal Neuralgia and the Need for Vigilance in Monitoring Adverse Drug Events: A Case Report. 三叉神经痛的治疗模式与监测药物不良事件的必要性：病例报告。

IF 1.1

Current drug safety Pub Date : 2024-01-01 DOI: 10.2174/0115748863215954231214073053

Raja Narendra Divakar Addanki, Anjali Srikanth Mannava, Hemasri Velmurugan, Pugazhenthan Thangaraju

引用次数: 0

Amoxicillin Induced Fever, Rash, and Catatonia - A Case Study. 阿莫西林诱发发热、皮疹和紧张症--病例研究。

IF 1.5

Current drug safety Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230308094209

Chunnu Kumar Yadav, Rajat Ranka, Prasan Kumar Panda, Bishal Pratap Shah, Mayank Kumar Mishra, Vijay Krishnan

引用次数: 0

Multiple Sclerosis Risk Among Anti-tumor Necrosis Factor Alpha Users: A Methodological Review of Observational Studies Based on Real-world Data. 抗肿瘤坏死因子α使用者患多发性硬化症的风险：基于真实世界数据的观察性研究的方法学回顾。

IF 1.5

Current drug safety Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230726162245

Lingyi Li, Mahyar Etminan, Gilaad G Kaplan, Helen Tremlett, Hui Xie, J Antonio Aviña-Zubieta

{"title":"Multiple Sclerosis Risk Among Anti-tumor Necrosis Factor Alpha Users: A Methodological Review of Observational Studies Based on Real-world Data.","authors":"Lingyi Li, Mahyar Etminan, Gilaad G Kaplan, Helen Tremlett, Hui Xie, J Antonio Aviña-Zubieta","doi":"10.2174/1574886318666230726162245","DOIUrl":"10.2174/1574886318666230726162245","url":null,"abstract":"Epidemiologic studies on the risk of multiple sclerosis (MS) or demyelinating events associated with anti-tumor necrosis factor alpha (TNFα) use among patients with rheumatic diseases or inflammatory bowel diseases have shown conflicting results. Causal directed acyclic graphs (cDAGs) are useful tools for understanding the differing results and identifying the structure of potential contributing biases. Most of the available literature on cDAGs uses language that might be unfamiliar to clinicians. This article demonstrates how cDAGs can be used to determine whether there is a confounder, a mediator or collider-stratification bias and when to adjust for them appropriately. We also use a case study to show how to control for potential biases by drawing a cDAG depicting anti-TNFα use and its potential to contribute to MS onset. Finally, we describe potential biases that might have led to contradictory results in previous studies that examined the effect of anti-TNFα and MS, including confounding, confounding by contraindication, and bias due to measurement error. Clinicians and researchers should be cognizant of confounding, confounding by contraindication, and bias due to measurement error when reviewing future studies on the risk of MS or demyelinating events associated with anti-TNFα use. cDAGs are a useful tool for selecting variables and identifying the structure of different biases that can affect the validity of observational studies.","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9877078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Methotrexate-induced Severe Pancytopenia in a Patient with Rheumatoid Arthritis: A Case Report and Review of Literature. 一名类风湿性关节炎患者甲氨蝶呤诱发的全血细胞严重减少：病例报告和文献综述。

IF 1.5

Current drug safety Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230516115737

Elham Hosseini, Foroud Shahbazi

引用次数: 1

Polymeric Micelles as Drug Delivery System: Recent Advances, Approaches, Applications and Patents. 作为给药系统的聚合物胶束：最新进展、方法、应用和专利。

IF 1.5

Current drug safety Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230605120433

Anushka Jain, Kamini Bhardwaj, Mukesh Bansal

{"title":"Polymeric Micelles as Drug Delivery System: Recent Advances, Approaches, Applications and Patents.","authors":"Anushka Jain, Kamini Bhardwaj, Mukesh Bansal","doi":"10.2174/1574886318666230605120433","DOIUrl":"10.2174/1574886318666230605120433","url":null,"abstract":"Administering therapeutics through the oral route is a pervasive and widely approved medication administration approach. However, it has been found that many drugs show low systemic absorption when delivered through this route. Such limitations of oral drug delivery can be overcome by polymeric micelles acting as vehicles. As a result, they improve drug absorption by protecting loaded drug substances from the gastrointestinal system's hostile conditions, allowing controlled drug release at a specific site, extending the time spent in the gut through mucoadhesion, and inhibiting the efflux pump from reducing therapeutic agent accumulation. To promote good oral absorption of a weakly water-soluble medicinal drug, the loaded medicine should be protected from the hostile atmosphere of the GI tract. Polymeric micelles can be stacked with a broad assortment of ineffectively dissolvable medications, improving bioavailability. This review discusses the major mechanism, various types, advantages, and limitations for developing the polymeric micelle system and certain micellar drug delivery system applications. The primary goal of this review is to illustrate how polymeric micelles can be used to deliver poorly water-soluble medications.","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9764005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Amphotericin-B-Induced Chronic Kidney Disease in a Post-COVID-19 Patient with Widespread Rhinocerebral Mucormycosis and Pneumonia: A Case Report. 一个病例报告：COVID-19 后患者的两性霉素-B 诱导的慢性肾病，患者患有广泛的犀脑粘液瘤病和肺炎：病例报告。

IF 1.1

Current drug safety Pub Date : 2024-01-01 DOI: 10.2174/1574886318666230804101539

Nishant Johri, Ambika Choudhary, Ujjawal Rawat, Maheshwari Vengat

{"title":"Amphotericin-B-Induced Chronic Kidney Disease in a Post-COVID-19 Patient with Widespread Rhinocerebral Mucormycosis and Pneumonia: A Case Report.","authors":"Nishant Johri, Ambika Choudhary, Ujjawal Rawat, Maheshwari Vengat","doi":"10.2174/1574886318666230804101539","DOIUrl":"10.2174/1574886318666230804101539","url":null,"abstract":"Background: The COVID-19 pandemic has posed a unique challenge to the medical community due to potential co-infections with bacteria and fungi. We report a case of Rhino cerebral mucormycosis infection in a 67-year-old patient after recovery from COVID-19.Objective: To report a case of Rhino cerebral mucormycosis in a 67-year-old patient with preexisting health conditions after recovering from COVID-19 and to highlight the importance of early detection and treatment of co-infections in patients with pre-existing health conditions.Case presentation: The patient had pre-existing health conditions, including uncontrolled diabetes, hypertension, and Chronic obstructive pulmonary disease (COPD), which made him more vulnerable to complications after COVID-19. He was admitted to the hospital after experiencing a dark discharge from his left eye, later confirmed to be due to mucormycosis. Histopathological examination revealed invasive mucormycosis, highlighting the importance of early detection and treatment. However, the patient experienced Acute kidney injury (AKI) after only 5 days of treatment with conventional amphotericin B, underscoring the need for careful monitoring and adjustment of treatment regimens.Discussion: The case underscores the need for early detection and treatment of co-infections in vulnerable patients. The patient's pre-existing conditions and immunocompromised state made him more susceptible to the infection. The case also highlights the importance of careful monitoring and adjustment of treatment regimens to minimize the risk of adverse effects.Conclusion: While COVID-19 has presented challenges and uncertainties, it has also provided valuable insights into the interactions between infectious agents and the human body. Continued research and vigilance are necessary to mitigate the impact of co-infections and improve outcomes for patients.","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9988645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0